Last reviewed · How we verify
NCT06069505: ARPO
Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study
trial testing Aspergillus PCR in Invasive Aspergillosis in 300 participants. Currently enrolling.
31 December 2030
Quick facts
| Lead sponsor | Bart Rijnders |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 July 2017 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Aspergillus PCR
Conditions studied
- Invasive Aspergillosis — all drugs for Invasive Aspergillosis →
Sponsor
Bart Rijnders
Who can join
18 and older, any sex, with Invasive Aspergillosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Invasive aspergillosis (IA) is the most common mould infection in immunocompromised patients with haematological disease. Voriconazole, a triazole, improves overall survival of patients with an IA and is the mainstay of therapy. Resistance of A. Fumigatus emerged as an important clinical problem and infections with azole resistant Aspergillus have a high mortality. Nowhere in the world, azole resistance is more prevalent than in the Netherlands. Rapid detection of resistance is key to improve the patient's outcome but fungal cultures take time and are often negative. The investigators aim to detect azole resistance associated mutations in fungal DNA extracted directly from serum or plasma to accelerate diagnosis and improve outcome of patients infected with azole resistant A. fumigatus.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06069505
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Invasive Aspergillosis
Currently open trials in the same condition.
- NCT06583512 — Treatment Duration of IPA · active not recruiting
- NCT06382922 — Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy · recruiting
- NCT05101187 — Olorofim Aspergillus Infection Study · Phase 3 · active not recruiting
- NCT03717623 — Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants · Phase 4 · recruiting
- NCT01386437 — Natural History of Individuals With Immune System Problems That Lead to Fungal Infections · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06069505 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bart Rijnders
- Last refreshed: 7 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06069505.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing